L Lisata Therapeutics
L
Slēgts
3.45 -0.58
Pārskats
Akcijas cenas izmaiņa
24h
Min
3.4
Max
3.52
Ienākumi | -1.5M -4.5M |
|---|---|
Peļņas marža | -2,954 |
Darbinieki | 21 |
Nākamie ieņēmumi | 2026. g. 6. aug. |
|---|
Tirgus kapitalizācija | 2.7M 26M |
|---|---|
Iepriekšējā atvēršanas cena | 4.03 |
Iepriekšējā slēgšanas cena | 3.45 |
Lisata Therapeutics Grafiks
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
Par Lisata Therapeutics
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
